IL-28A/IFN-lambda 2 Antibody (248526) [Unconjugated]

Recombinant HumanIL‑28A/IFN‑ lambda 2 (Catalog #1587‑IL) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HepG2 human hepatocellular carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recom­binant Human IL‑28A/IFN‑ lambda 2 (0.1 µg/mL) is neutralized (green line) by increasing concentrations of Mouse Anti‑Human IL‑28A/IFN‑ lambda 2 Monoclonal Antibody (Catalog # MAB1587). The ND50 is typically 0.25‑1.0 µg/mL.

• Reactivity: Hu
• Applications: B/N
• Clone: 248526
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: LYOPH

IL-28A/IFN-lambda 2 Antibody (248526) [Unconjugated] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human IL‑28A/IFN‑ lambda 2
  Val26-Val200
  Accession # Q8IZJ0
• Specificity: Detects human IL‑28A/IFN‑ lambda 2 in direct ELISAs. In direct ELISAs, 83% cross-reactivity with recombinant human (rh) IL-28B/IFN-lambda 3 and no cross-reactivity with recombinant mouse IL-28B/IFN-lambda 3 or rhIL-29/IFN-l1 is observed.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: IFNL2
• Purity Statement: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • Neutralization 1-8 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-28A/IFN-lambda 2 Antibody (248526) [Unconjugated]

• interleukin-28A
• IFN-lambda 2
• IL28A
• IL-28A
• interferon, lambda 2

Background

IL-28A, IL-28B, and IL-29, also named interferon-lambda 2 (IFN-lambda 2), IFN-lambda 3, and IFN-lambda 1, respectively, are class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11‑13% aa sequence identity) and type I IFN family (15‑19% aa sequence identity) (1‑3). The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and
up‑regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL‑10 receptor  beta
(IL‑10 R beta ) and a novel IL‑28 receptor alpha (IL‑28 R alpha , also known as IFN-lambda R1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation. The phosphorylated STAT1 and STAT2 complex with IFN-regulatory factor 9 (IRF-9) to form the IFN-stimulated regulatory factor 3 (ISGF-3) transcription factor complex that is translocated to the nucleus. ISGF-3 binds to the IFN-stimulated response element (ISRE) present in the regulatory regions of the target genes. Human IL-28A cDNA encodes a 200 amino acid (aa) residue precursor protein with a 25 aa signal peptide. It shares 94% and 67% aa sequence identity with human IL-28B and human IL-29, respectively.

1. Vilcek, J. (2003) Nature Immunol. 4:8.
2. Sheppard, P. et al. (2003) Nature Immunol. 4:63.
3. Kotenko, S.V. et al. (2003) Nature Immunol. 4:69.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for IL-28A/IFN-lambda 2 Antibody (MAB1587)(3)

Publications using MAB1587

• Groen, K;Kuratli, R;Sar, L;Vasou, A;Huber, M;Hughes, DJ;Hale, BG; Highly sensitive reporter cell line for detection of interferon types I-III and their neutralization by antibodies European journal of immunology 2024-10-04 [PMID: 39367550] (Neutralization, Human)
• J Hong, JH Lee, Z Zhang, Y Wu, M Yang, Y Liao, R de la Rosa, J Scheirer, D Pechacek, N Zhang, Z Xu, T Curiel, X Tan, TH Huang, K Xu PRC2-mediated epigenetic suppression of type I IFN-STAT2 signaling impairs antitumor immunity in luminal breast cancer Cancer Research, 2022-12-16;0(0):. 12/16/2022 [PMID: 36222718]
• Yin Z, Dai J, Deng J, Sheikh F, Natalia M, Shih T, Lewis-Antes A, Amrute S, Garrigues U, Doyle S, Donnelly R, Kotenko S, Fitzgerald-Bocarsly P Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J Immunol, 2012-08-13;189(6):2735-45. 2012-08-13 [PMID: 22891284] (Flow Cytometry, Human)

Bioinformatics

• Gene Symbol: IFNL2
• Uniprot:
  • Q8IZJ0()